Cargando…

Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes

BACKGROUND: Liraglutide was first released in Japan as a long-acting once-daily glucagon-like peptide-1 receptor agonist. The maximum dose in Japan is 0.9 mg/day, which is half of that used in the United States and the European Union (1.8 mg/day). The efficacy of this maximum allowable dose of lirag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ito, Daisuke, Iuchi, Takujiro, Kurihara, Susumu, Inoue, Ikuo, Katayama, Shigehiro, Inukai, Kouichi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2015
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4522987/ https://www.ncbi.nlm.nih.gov/pubmed/26251684 http://dx.doi.org/10.14740/jocmr2237w

Ejemplares similares

The Efficacy of Vildagliptin Concomitant With Insulin Therapy in Type 2 Diabetic Subjects
por: Ito, Daisuke, et al.
Publicado: (2015)

Effects of Dapagliflozin Compared with Sitagliptin and Metformin in Drug-Naïve Japanese Patients with Type 2 Diabetes: A 12-Week, Open-Label, Randomized, Active-Controlled Trial
por: Ito, Daisuke, et al.
Publicado: (2021)

Adiponectin Upregulates Ferritin Heavy Chain in Skeletal Muscle Cells
por: Ikegami, Yuichi, et al.
Publicado: (2009)

Long-Term Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: 104-Week Follow-up of an Open-Label Study
por: Ito, Daisuke, et al.
Publicado: (2018)

Administration of thiamazole for Graves’ disease might trigger the onset of type 1 diabetes
por: Mizutani, Gen, et al.
Publicado: (2018)

Intrinsic insulin secretion capacity might be preserved by discontinuing anti‐programmed cell death protein 1 antibody treatment in ‘anti‐programmed cell death protein 1 antibody‐induced’ fulminant type 1 diabetes
por: Sakai, Gota, et al.
Publicado: (2018)

Effects of Ipragliflozin on Diabetic Nephropathy and Blood Pressure in Patients With Type 2 Diabetes: An Open-Label Study
por: Ito, Daisuke, et al.
Publicado: (2017)

Efficacy of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight, eating behavior, and glycemic control, in Japanese obese type 2 diabetes
por: Fujishima, Yuya, et al.
Publicado: (2012)

Liraglutide in Adults with Type 2 Diabetes: Global Perspective on Safety, Efficacy and Patient Preference
por: Yabe, Daisuke, et al.
Publicado: (2011)

Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes
por: Tonoike, Mie, et al.
Publicado: (2018)

Efficacy of liraglutide therapy in Japanese type 2 diabetic patients insufficiently controlled with basal‐supported oral therapy
por: Takahara, Mitsuyoshi, et al.
Publicado: (2012)

Weight control before and during pregnancy for patients with gestational diabetes mellitus
por: Yasuda, Shigemitsu, et al.
Publicado: (2019)

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
por: Neumiller, Joshua J, et al.
Publicado: (2010)

Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes
por: Inoue, Kana, et al.
Publicado: (2011)

Effects of liraglutide on postprandial insulin and glucagon responses in Japanese patients with type 2 diabetes
por: Matsumoto, Shinobu, et al.
Publicado: (2013)

Clinical and psychological characteristics of liraglutide treatment among patients with type 2 diabetes
por: Al Hayek, Ayman A., et al.
Publicado: (2020)

Is a Switch From Insulin Therapy to Liraglutide Possible in Japanese Type 2 Diabetes Mellitus Patients?
por: Kawata, Takehiro, et al.
Publicado: (2014)

Liraglutide is effective in type 2 diabetic patients with sustained endogenous insulin‐secreting capacity
por: Kozawa, Junji, et al.
Publicado: (2012)

Liraglutide in the management of type 2 diabetes
por: Wajcberg, Estela, et al.
Publicado: (2010)

A randomized trial to investigate the efficacy and safety of once‐daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg
por: Seino, Yutaka, et al.
Publicado: (2022)

Disease duration as an indicator of the efficacy of liraglutide in patients with type 2 diabetes mellitus
por: Wilbrink, Francis J, et al.
Publicado: (2018)

Retrospective analysis of safety and efficacy of insulin‐to‐liraglutide switch in Japanese type 2 diabetes: A caution against inappropriate use in patients with reduced β‐cell function
por: Usui, Ryota, et al.
Publicado: (2013)

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
por: Nauck, Michael, et al.
Publicado: (2009)

Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trials
por: Dejgaard, Thomas F., et al.
Publicado: (2021)

Predicting Macro- and Microvascular Complications in Type 2 Diabetes: The Japan Diabetes Complications Study/the Japanese Elderly Diabetes Intervention Trial risk engine
por: Tanaka, Shiro, et al.
Publicado: (2013)

Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study
por: Tanaka, Kenichi, et al.
Publicado: (2022)

Meta-analysis of the efficacy of liraglutide in patients with type 2 diabetes accompanied by incipient nephropathy
por: Liu, Wei, et al.
Publicado: (2019)

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics
por: Jacobsen, Lisbeth V., et al.
Publicado: (2015)

Clinical Characteristics and Satisfaction of Liraglutide Treatment among Patients with Type 2 Diabetes: A Prospective Study
por: Al Hayek, Ayman A, et al.
Publicado: (2019)

Potential of liraglutide in the treatment of patients with type 2 diabetes
por: Deacon, Carolyn F
Publicado: (2009)

Comparative effectiveness of liraglutide in the treatment of type 2 diabetes
por: Rigato, Mauro, et al.
Publicado: (2014)

Prediction scale of response to liraglutide therapy as the method for increase of treatment efficacy in type 2 diabetes
por: Mosikian, Anna A, et al.
Publicado: (2022)

Efficacy and safety of liraglutide in patients with type 2 diabetes mellitus and severe obstructive sleep apnea
por: Jiang, Wenlong, et al.
Publicado: (2022)

Superior efficacy with a fixed‐ratio combination of insulin degludec and liraglutide (IDegLira) compared with insulin degludec and liraglutide in insulin‐naïve Japanese patients with type 2 diabetes in a phase 3, open‐label, randomized trial
por: Kaku, Kohei, et al.
Publicado: (2019)

Liraglutide in people treated for type 2 diabetes with multiple daily insulin injections: randomised clinical trial (MDI Liraglutide trial)
por: Lind, Marcus, et al.
Publicado: (2015)

Diabetic Retinopathy and Microalbuminuria Can Predict Macroalbuminuria and Renal Function Decline in Japanese Type 2 Diabetic Patients: Japan Diabetes Complications Study
por: Moriya, Tatsumi, et al.
Publicado: (2013)

Efficacy and Safety of a Biosimilar Liraglutide (Melitide(®)) Versus the Reference Liraglutide (Victoza(®)) in People with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Noninferiority Clinical Trial
por: Esteghamati, Alireza, et al.
Publicado: (2023)

Non-diabetic use of liraglutide
por: Verma, Abhyudaya
Publicado: (2012)

Effects of DPP‐4 inhibitor linagliptin and GLP‐1 receptor agonist liraglutide on physiological response to hypoglycaemia in Japanese subjects with type 2 diabetes: A randomized, open‐label, 2‐arm parallel comparative, exploratory trial
por: Yabe, Daisuke, et al.
Publicado: (2016)

Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease
por: Verma, Subodh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7o2c147tnddcetq52lja34r0ql